Stockreport

Transient but transformative: Sanofi's mRNA CAR-T enters in vivo race [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF the body, bypassing the weeks-long ex vivo manufacturing required for ex vivo CAR-Ts. The platform uses mRNA to instruct the cell to produce the chimeric antigen recepto [Read more]